arc in Medical Technology
Navigation Links
arc in Medical Technology
ATLANTA, Feb. 13 /PRNewswire/ -- On Thursday, January 31, General
Hospital Vienna successfully completed its first Volumetric Modulated Arc
Therapy (VMAT)* treatment. The hospital is one of the first in the world to
carry out this innovative cancer treatment option.
(Logo: http://www.newsco...
...ic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)*. The arc definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials. ...
... stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The arc definitions of stent thrombosis were developed to eliminate variability in ...bosis between one and two years, defined as very late stent thrombosis, per arc definition of definite/probable stent thrombosis (0.3 percent for XIENCE V ...
...nt (p=0.0098), a relative reduction of 46 percent. arc definite/probable total stent thrombosis at two ye... years using either the Protocol definition or the arc definite/probable definition while the TAXUS Expre...ocol definition and 1.5 percent (p=0.24) using the arc definition. "The next-generation TAXUS Liberte S...
... years showed that diabetic patients treated with the TAXUS Stent in the ARRIVE registry had similar rates of MI (3.1% vs. 2.5%, p=0.35, adjusted) and arc definite/probable stent thrombosis (2.3% vs. 1.9%, p=0.34, adjusted) compared to non-diabetic patients, whether or not multivariate adjustment was use...
... and TLR) rate was 7.3% for the XIENCE V (PROMUS) Stent and 12.8% for the TAXUS Express Stent (p=0.004). In addition, stent thrombosis rates using the arc (Academic Research Consortium) definite/probable definition were low for the XIENCE V (PROMUS) and the TAXUS Express Stents (1.3% and 1.7%, p=0.77). ...
...(0.3 percent for XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol (0.2 percent for XIENCE V and 1.0 percent for TAXUS). The arc definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials. "From t...
...ion. Rates of definite/probable late stent thrombosis at one year under the arc definition were 0.5 percent for XIENCE V and 0.6 percent for TAXUS. The arc definition of late stent thrombosis was developed to eliminate variability ...
...S in diabetics, with no significant differences in death (7.3% vs. 7.1%, p=0.91), cardiac death (4.6% vs. 2.7%, p=0.23), MI (6.5% vs. 6.6%, p=0.83) or arc Definite/Probable stent thrombosis (1.6% vs. 1.5%, p=1.00) in TAXUS and BMS, respectively. "We are pleased to see that TLR in TAXUS patients -- an i...
...bosis under the Dublin/Academic Research Consortium (ARC) definition were 0.9 percent for XIENCE V and 1.4 percent for TAXUS at two years. The arc definition of late-stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials. "In ...
...osis at one year was low and showed no significant difference between diabetics and non-diabetics under Protocol definition (1.5% vs. 1.3%, p=0.59) or arc Definite/Probable (1.7% vs. 1.2%, p=0.29). Unadjusted one-year rates of TAXUS Stent-related cardiac death, TAXUS Stent-related MCE, TAXUS Stent-relate...
...otal project funding, include: -- Salisbury-based AHPharma Food Safety Products Inc. and the University of Maryland Eastern Shore: Underwater Pulsed arc Discharge (UPAD) for Poultry; $251,703 -- Arnold-based Applied Sensor Research and Development Corp. and the University of Maryland, College Park: P...
...s at one year per protocol were 0.3 percent for XIENCE V and 0.6 percent for TAXUS. Rates of definite/probable late stent thrombosis at one year under arc definition were 0.5 percent for XIENCE V and 0.6 percent for TAXUS. A variety of SPIRIT III subgroup analyses showed additional observational evidenc...
...thrombosis rates through one year were also low for both the TAXUS Stent (0.6%, 0.6%) and the XIENCE V (PROMUS) Stent (0.8%, 1.1%), using protocol and arc definitions, respectively. "The SPIRIT III one-year data reaffirms the proven long-term outcomes of the TAXUS Stent," said Paul LaViolette, Chief Ope...
...thrombosis rates for the CYPHER(R) Stent using the arc definitions. The definite, definite/probable and d...tent and the bare metal stent were not possible as arc stent thrombosis rates for the ARTS I Study were n...was 2.8 percent at 30 days of follow-up, while the arc definite definite/probable and definite/probable/p...
...d a stent thrombosis rate of 4.2 percent for the CYPHER(R) Stent versus 1.7 percent for the bare metal stent (p=0.199). The definite/probable/possible arc definition yielded a stent thrombosis rate of 6.5 percent for the CYPHER(R) Stent versus 3.5 percent for the bare metal stent (p=0.216). While there w...
...IRIT II European Clinical Trial Results Demonstrate Continued Safety with XIENCE V; Zero Late Stent Thrombosis in SPIRIT FIRST and SPIRIT II Under New arc Definition In the important clinical endpoint of MACE, one-year follow-up results from 300 patients enrolled in Abbott's randomized SPIRIT II Europe...
...igators did not find significant differences in the stent thrombosis rates between the ARTS II diabetic and non-diabetic patients using any of the arc definitions. The CYPHER(R) Stent does not have an approved indication in the United States for diabetic patients or patients with multivessel ...
...RRIVE 1 and 2. More than 30 baseline characteristics were assessed as predictors of stent thrombosis at various time periods up to two years using the arc (Academic Research Consortium) definition of "definite plus probable, total." Stent thrombosis is a rare but serious adverse event that can occur with...
...ntations of Endeavor data during the last year, with consistent and predictable results. Using either the pre-specified protocol definition or the new arc definitions, these data demonstrate that Endeavor is highly effective at preventing repeat procedures without an increased safety risk, and with a fav...
... "The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and arc definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigat...
...ic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)*. The arc definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials. ...
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
...ombosis (1.3 percent for XIENCE V vs. 1.7 percent for TAXUS) and per the SPIRIT III protocol (1.0 percent for XIENCE V vs. 1.7 percent for TAXUS). The arc definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials. -- Among p...... stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The arc definitions of stent thrombosis were developed to eliminate variability in ...bosis between one and two years, defined as very late stent thrombosis, per arc definition of definite/probable stent thrombosis (0.3 percent for XIENCE V ...
...nt (p=0.0098), a relative reduction of 46 percent. arc definite/probable total stent thrombosis at two ye... years using either the Protocol definition or the arc definite/probable definition while the TAXUS Expre...ocol definition and 1.5 percent (p=0.24) using the arc definition. "The next-generation TAXUS Liberte S...
... years showed that diabetic patients treated with the TAXUS Stent in the ARRIVE registry had similar rates of MI (3.1% vs. 2.5%, p=0.35, adjusted) and arc definite/probable stent thrombosis (2.3% vs. 1.9%, p=0.34, adjusted) compared to non-diabetic patients, whether or not multivariate adjustment was use...
Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
...nt with pancreatic cancer recently became the first person in the United States to receive treatment using Elekta VMAT (Volumetric intensity Modulated arc Therapy) at Seattle's Swedish Cancer Institute. This revolutionary new technology dramatically decreases treatment times -- delivering a higher dose t...... and TLR) rate was 7.3% for the XIENCE V (PROMUS) Stent and 12.8% for the TAXUS Express Stent (p=0.004). In addition, stent thrombosis rates using the arc (Academic Research Consortium) definite/probable definition were low for the XIENCE V (PROMUS) and the TAXUS Express Stents (1.3% and 1.7%, p=0.77). ...
...(0.3 percent for XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol (0.2 percent for XIENCE V and 1.0 percent for TAXUS). The arc definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials. "From t...
...ion. Rates of definite/probable late stent thrombosis at one year under the arc definition were 0.5 percent for XIENCE V and 0.6 percent for TAXUS. The arc definition of late stent thrombosis was developed to eliminate variability ...
...S in diabetics, with no significant differences in death (7.3% vs. 7.1%, p=0.91), cardiac death (4.6% vs. 2.7%, p=0.23), MI (6.5% vs. 6.6%, p=0.83) or arc Definite/Probable stent thrombosis (1.6% vs. 1.5%, p=1.00) in TAXUS and BMS, respectively. "We are pleased to see that TLR in TAXUS patients -- an i...
...bosis under the Dublin/Academic Research Consortium (ARC) definition were 0.9 percent for XIENCE V and 1.4 percent for TAXUS at two years. The arc definition of late-stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials. "In ...
...osis at one year was low and showed no significant difference between diabetics and non-diabetics under Protocol definition (1.5% vs. 1.3%, p=0.59) or arc Definite/Probable (1.7% vs. 1.2%, p=0.29). Unadjusted one-year rates of TAXUS Stent-related cardiac death, TAXUS Stent-related MCE, TAXUS Stent-relate...
...otal project funding, include: -- Salisbury-based AHPharma Food Safety Products Inc. and the University of Maryland Eastern Shore: Underwater Pulsed arc Discharge (UPAD) for Poultry; $251,703 -- Arnold-based Applied Sensor Research and Development Corp. and the University of Maryland, College Park: P...
Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
...f cardiac death and Q-wave myocardial infarction were identical between the TAXUS Stent and the control BMS (5.3% vs. 5.3%, p=0.96). Using the broader arc definition of definite/probable, the TAXUS IV trial reported no cases of stent thrombosis between years four and five for the TAXUS Stent and one inci...Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
...no stent thrombosis at 284 days using either the Protocol Definition or the arc Definition while the TAXUS Express control Stent reported 0.7% (p=0.49) using the Protocol Definition and 1.4% (p=0.24) using the arc Definition. The Company received the CE Mark for the TAXUS Liberte Stent i......s at one year per protocol were 0.3 percent for XIENCE V and 0.6 percent for TAXUS. Rates of definite/probable late stent thrombosis at one year under arc definition were 0.5 percent for XIENCE V and 0.6 percent for TAXUS. A variety of SPIRIT III subgroup analyses showed additional observational evidenc...
...thrombosis rates through one year were also low for both the TAXUS Stent (0.6%, 0.6%) and the XIENCE V (PROMUS) Stent (0.8%, 1.1%), using protocol and arc definitions, respectively. "The SPIRIT III one-year data reaffirms the proven long-term outcomes of the TAXUS Stent," said Paul LaViolette, Chief Ope...
...thrombosis rates for the CYPHER(R) Stent using the arc definitions. The definite, definite/probable and d...tent and the bare metal stent were not possible as arc stent thrombosis rates for the ARTS I Study were n...was 2.8 percent at 30 days of follow-up, while the arc definite definite/probable and definite/probable/p...
...d a stent thrombosis rate of 4.2 percent for the CYPHER(R) Stent versus 1.7 percent for the bare metal stent (p=0.199). The definite/probable/possible arc definition yielded a stent thrombosis rate of 6.5 percent for the CYPHER(R) Stent versus 3.5 percent for the bare metal stent (p=0.216). While there w...
...IRIT II European Clinical Trial Results Demonstrate Continued Safety with XIENCE V; Zero Late Stent Thrombosis in SPIRIT FIRST and SPIRIT II Under New arc Definition In the important clinical endpoint of MACE, one-year follow-up results from 300 patients enrolled in Abbott's randomized SPIRIT II Europe...
...igators did not find significant differences in the stent thrombosis rates between the ARTS II diabetic and non-diabetic patients using any of the arc definitions. The CYPHER(R) Stent does not have an approved indication in the United States for diabetic patients or patients with multivessel ...
...RRIVE 1 and 2. More than 30 baseline characteristics were assessed as predictors of stent thrombosis at various time periods up to two years using the arc (Academic Research Consortium) definition of "definite plus probable, total." Stent thrombosis is a rare but serious adverse event that can occur with...
...ntations of Endeavor data during the last year, with consistent and predictable results. Using either the pre-specified protocol definition or the new arc definitions, these data demonstrate that Endeavor is highly effective at preventing repeat procedures without an increased safety risk, and with a fav...
... "The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and arc definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigat...
Other TagsSharpSharpOrissaPopularityCouplesAdolescentsWorriedEncephalitisEncephalitisOutpatientSunscreenCured
SharpOrissaPopularityPromotingRemifeminCouplesAdolescentsWorriedArthiritisEncephalitisOutpatientAstrocytesSunscreenCured
Breaking Biology News(10 mins):University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids 2Canna can: Ornamental eliminates pollutants from stormwater runoff 2Lose the fat 3A Targeting grease to curtail sewer overflows 10859 1Lose the fat 3A Targeting grease to curtail sewer overflows 10859 2Intensive land management leaves Europe without carbon sinks 10857 1Intensive land management leaves Europe without carbon sinks 10857 2BridgeGate Launches New Healthcare Integration and Interoperability Products 61926 1BridgeGate Launches New Healthcare Integration and Interoperability Products 61926 2BridgeGate Launches New Healthcare Integration and Interoperability Products 61926 3BridgeGate Launches New Healthcare Integration and Interoperability Products 61926 4
Breaking Medicine News(10 mins):Health News:Depression Survey: Implications for Diverse Communities 2Health News:Depression Survey: Implications for Diverse Communities 3Health News:Approval of Michigan Smoke-Free Legislation is Historic Win for Health 2Health News:Approval of Michigan Smoke-Free Legislation is Historic Win for Health 3Health News:Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting 2Health News:Weight Watchers Declares Quarterly Dividend 2
Other Contentsnursingnursingnursingnursingnursingnursingnosocomialnosocomialobesityobesityobesityobesityobesityobesityobesitynystagmusobsessionobsessionobsessioncompulsivecompulsiveobsessiveobsessiveobstetricsobstetricsobstetricsobstetrics[1] Depression Survey: Implications for Diverse Communities [1] Approval of Michigan Smoke-Free Legislation is Historic Win for Health[0] University of Maryland chemist receives Astellas Award for blindness prevention research[1] Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting[0] Weight Watchers Declares Quarterly Dividend
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |